Physician profile
Bruce L Roach
NPI 1255402301
$893.30
in general payments reported to CMS, 2019-2025
16 companies · $78.55 in 2025
The $78.55 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $284 · 2020: $79.89 · 2021: $63.71 · 2022: $79.57 · 2023: $271 · 2024: $36.99 · 2025: $78.55.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $386.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $386.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $263.17 | 2019-2025 | Jardiance, Tradjenta |
| Novartis Pharmaceuticals Corporation | $73.23 | 2019-2023 | |
| Lilly USA, LLC | $71.38 | 2023 | Mounjaro |
| Glaxosmithkline, LLC. | $62.29 | 2019-2023 | Arexvy, Bexsero, Shingrix |
| Astrazeneca Pharmaceuticals LP | $59.20 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $59.14 | 2019 | |
| Astellas Pharma US INC | $58.64 | 2019-2022 | |
| Pfizer INC. | $40.55 | 2019-2022 | |
| Amgen INC. | $39.33 | 2023 | Repatha, Otezla |
| Novo Nordisk INC | $28.18 | 2019-2023 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $26.81 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.76 | 2019-2021 | |
| Orexo US, INC. | $24.71 | 2022 | |
| Abbvie INC. | $23.07 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.68 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $16.16 | 2025 | The Cologuard Plus Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Roach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.